Our results obtained in p53 wild-type and p53-mutant cells as well as in p53-depleted cells indicated that p53 activation is of relevance for the anti-cancer effects exerted by aurora kinase inhibitors in neuroblastoma cells. The gene discussed is TP53; the disease is cancer.